BACKGROUND: The apolipoproteins (APOA1/C3/A4/A5) are key components in modulating lipoprotein metabolism. It is unknown whether variants at the APOA1/C3/A4/A5 gene cluster are associated with lipid response to pharmacologic intervention. METHODS AND RESULTS: Plasma triglycerides (TGs) and high-density lipoprotein (HDL) levels were measured in 861 Genetics of Lipid-Lowering Drugs and Diet Network study participants who underwent a 3-week fenofibrate trial. We examined 18 common single nucleotide polymorphisms (SNPs) spanning the APOA1/C3/A4/A5 genes to investigate the effects of variants at the gene cluster on lipid response to fenofibrate treatment. We found that the minor alleles of the SNPs rs3135506 (APOA5_S19W), rs5104 (APOA4_N147S), rs4520 (APOC3_G34G), and rs5128 (APOC3_3U386) were associated with enhanced TG response to fenofibrate treatment (P= 0.0004-0.018). The minor allele of SNP rs2854117 (APOC3_M482) was associated with reduced rather than enhanced TG response (P= 0.026). The SNP rs3135506 (APOA5_S19W) was associated with HDL response, with minor allele related to reduced HDL response to fenofibrate (P= 0.002). Association analyses on haplotype provided corroborative evidence to single SNP association analyses. The common haplotypes H2, H3, and H5 were significantly associated with reduced TG response to fenofibrate. CONCLUSION: The genetic variants at APOA1/C3/A4/A5 gene cluster may be useful markers to predict response of lipid-lowering therapy with fenofibrate. Further studies to replicate/confirm our findings are warranted.
BACKGROUND: The apolipoproteins (APOA1/C3/A4/A5) are key components in modulating lipoprotein metabolism. It is unknown whether variants at the APOA1/C3/A4/A5 gene cluster are associated with lipid response to pharmacologic intervention. METHODS AND RESULTS: Plasma triglycerides (TGs) and high-density lipoprotein (HDL) levels were measured in 861 Genetics of Lipid-Lowering Drugs and Diet Network study participants who underwent a 3-week fenofibrate trial. We examined 18 common single nucleotide polymorphisms (SNPs) spanning the APOA1/C3/A4/A5 genes to investigate the effects of variants at the gene cluster on lipid response to fenofibrate treatment. We found that the minor alleles of the SNPs rs3135506 (APOA5_S19W), rs5104 (APOA4_N147S), rs4520 (APOC3_G34G), and rs5128 (APOC3_3U386) were associated with enhanced TG response to fenofibrate treatment (P= 0.0004-0.018). The minor allele of SNP rs2854117 (APOC3_M482) was associated with reduced rather than enhanced TG response (P= 0.026). The SNP rs3135506 (APOA5_S19W) was associated with HDL response, with minor allele related to reduced HDL response to fenofibrate (P= 0.002). Association analyses on haplotype provided corroborative evidence to single SNP association analyses. The common haplotypes H2, H3, and H5 were significantly associated with reduced TG response to fenofibrate. CONCLUSION: The genetic variants at APOA1/C3/A4/A5 gene cluster may be useful markers to predict response of lipid-lowering therapy with fenofibrate. Further studies to replicate/confirm our findings are warranted.
Authors: Daniel O Stram; Christopher A Haiman; Joel N Hirschhorn; David Altshuler; Laurence N Kolonel; Brian E Henderson; Malcolm C Pike Journal: Hum Hered Date: 2003 Impact factor: 0.444
Authors: L A Pennacchio; M Olivier; J A Hubacek; J C Cohen; D R Cox; J C Fruchart; R M Krauss; E M Rubin Journal: Science Date: 2001-10-05 Impact factor: 47.728
Authors: Michael Olivier; Xujing Wang; Regina Cole; Brian Gau; Jessica Kim; Edward M Rubin; Len A Pennacchio Journal: Genomics Date: 2004-05 Impact factor: 5.736
Authors: Sophie Eichenbaum-Voline; Michael Olivier; Emma L Jones; Rossitza P Naoumova; Bethan Jones; Brian Gau; Hetal N Patel; Mary Seed; D John Betteridge; David J Galton; Edward M Rubin; James Scott; Carol C Shoulders; Len A Pennacchio Journal: Arterioscler Thromb Vasc Biol Date: 2003-10-09 Impact factor: 8.311
Authors: Philippa J Talmud; Steve Martin; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne Journal: J Lipid Res Date: 2004-01-16 Impact factor: 5.922
Authors: Carlos Lahoz; Rocío Peña; Jose M Mostaza; Javier Jiménez; Enric Subirats; Xavier Pintó; Manuel Taboada; Angela López-Pastor Journal: Atherosclerosis Date: 2003-06 Impact factor: 5.162
Authors: Xin Geng; Marguerite R Irvin; Bertha Hidalgo; Stella Aslibekyan; Vinodh Srinivasasainagendra; Ping An; Alexis C Frazier-Wood; Hemant K Tiwari; Tushar Dave; Kathleen Ryan; Jose M Ordovas; Robert J Straka; Mary F Feitosa; Paul N Hopkins; Ingrid Borecki; Michael A Province; Braxton D Mitchell; Donna K Arnett; Degui Zhi Journal: J Lipid Res Date: 2018-02-20 Impact factor: 5.922
Authors: Mary F Feitosa; Ping An; Jose M Ordovas; Shamika Ketkar; Paul N Hopkins; Robert J Straka; Donna K Arnett; Ingrid B Borecki Journal: Atherosclerosis Date: 2011-01-21 Impact factor: 5.162
Authors: Ariel Brautbar; Maja Barbalic; Fengju Chen; John Belmont; Salim S Virani; Steve Scherer; Robert A Hegele; Christie M Ballantyne Journal: J Lipid Res Date: 2013-04-30 Impact factor: 5.922